CPN and IVAX take home honours
Prague – A biotech company and a pharmaceutical enterprise are the winners of this year’s “Investor of the Year” competition, which is organised by CzechInvest and the country’s Association for Foreign Investment. At the end of June, pharmaceutical company IVAX and Czech biotechnology firm CPN were granted the trophy by industry minister Vladimír Tošovský at the Troja Chateau in Prague.
IVAX Pharmaceuticals (Opava), a daughter firm of Israeli generics producer Teva, was granted the award for building a new production plant for drugs – most of which will be exported to the US – at Opava worth CZK1bn (EUR38.5m).
Biotech-start-up CPN spol. sro. (Dolni Dobruc), which belongs to the ContiPro group, took the honours in the category “Investments with the greatest innovation potential”. The company synthesises hyaluronic acid, which is used as a raw material in the pharmaceutical and cosmetics industries. As a second pillar of its business, the firm manufactures preparations for wound-healing, tissue engineering, regenerative medicine and drug delivery, according to CPN director Vladimir Velebny.
For the first time in the history of the contest, there were more projects involving research and development or services than manufacturing.